Clinical trials: Platinum Sensitive
Ovarian Cancer
Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
The study was to evaluate the efficacy and safety of avelumab in combination with M6620 + carboplatin in participants with PARPi-resistant, recurrent, platinum sensitive ovarian, primary peritoneal, or fallopian tube cancer.
- Trial name
- NCT03704467
- Testing
- M6620, Avelumab, Carboplatin
- Where
- 13 sites in United States, Belgium and 1 more
- Volunteers
- 3 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Ovarian Cancer
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
This study will evaluate the efficacy and safety of pertuzumab in combination with carboplatin-based standard chemotherapy in patients with platinum-sensitive recurrent ovarian cancer.
- Trial name
- NCT02004093
- Testing
- pertuzumab, paclitaxel, gemcitabine
- Where
- 34 sites in Belgium, Canada and 7 more
- Volunteers
- 149 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Ovarian Cancer
A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer
This is a parallel arm study to evaluate AGS-8M4 administered in combination with chemotherapy in subjects with ovarian cancer. AGS-8M4 will be administered as an IV infusion until disease worsens.
- Conditions
- Carcinoma, Ovarian Cancer, Ovarian Diseases, Ovarian Neoplasms
- Trial name
- NCT01016054
- Testing
- AGS-8M4, Pegylated liposomal doxorubicin (PLD), gemcitabine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Astellas Pharma Inc
BRCA or HRR+ Mutated Ovarian Cancer Patients
To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer
This is a prospective, open-label, single arm, multi-center study to assess the real world clinical effectiveness and safety of olaparib maintenance monotherapy as the capsule formulation (in line with the EU approved prescribing…
- Trial name
- ORZORA (NCT02476968)
- Testing
- Olaparib
- Where
- 58 sites in Bulgaria, Canada and 6 more
- Volunteers
- 181 people
- Sponsor
- AstraZeneca
Small Cell Lung Cancer
A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer
The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.
- Trial name
- NCT03898791
- Testing
- LY3295668 Erbumine
- Where
- 40 sites in United States, Belgium and 6 more
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
Small Cell Lung Cancer
Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer
This is a Phase II research study that is designed for patients who have small cell lung cancer (SCLC) that is no longer responding to treatment.
- Trial name
- NCT00116610
- Testing
- picoplatin
- Where
- 55 sites in United States, Canada and 1 more
- Volunteers
- 75 people
- Sponsor
- Poniard Pharmaceuticals
High Grade Ovarian Cancer, Primary Peritoneal Cancer
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum sensitive, high-grade…
- Conditions
- High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT05456685
- Testing
- Mirvetuximab soravtansine, Carboplatin
- Where
- 69 sites in United States, Belgium and 4 more
- Volunteers
- 125 people
- Sponsor
- AbbVie
Ovarian Cancer
A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
The purpose of this study is to evaluate the effect of BSI-201 on the objective response rate in platinum-sensitive recurrent ovarian cancer patients receiving gemcitabine and carboplatin.
- Trial name
- NCT01033123
- Testing
- BSI-201
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Sanofi
Ovarian Cancer
A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
The purpose of this study is to evaluate the effect of BSI-201 on the objective response rate in platinum-resistant recurrent ovarian cancer patients receiving gemcitabine and carboplatin.
- Trial name
- NCT01033292
- Testing
- BSI-201
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Sanofi
Small Cell Lung Cancer
Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)
This is a Phase II, open-label, multicenter, single-arm, exploratory "proof of concept" study. Diflomotecan (7 mg fixed dose) will be administered as a 20-minute IV infusion once every 3 weeks in patients with sensitive small…
- Trial name
- NCT00080015
- Testing
- Diflomotecan (BN80915)
- Volunteers
- 9 people
- Sponsor
- Ipsen
Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
This is an open-label, phase 1/1b, dose-escalation, multicenter and multinational trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab, or Pembrolizumab and Pegylated Liposomal…
- Conditions
- Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma
- Trial name
- PROTA (NCT05271318)
- Testing
- TILT-123, pembrolizumab, pegylated liposomal doxorubicin
- Where
- 3 sites in United States, Finland
- Volunteers
- 29 people
- Sponsor
- TILT Biotherapeutics Ltd.
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246
The purpose of this study is to make a preliminary assessment of the efficacy of a combined APR-246 and carboplatin/PLD chemotherapy regimen, compared with carboplatin/PLD chemotherapy regimen alone, in patients with platinum…
- Trial name
- NCT02098343
- Testing
- APR-246, Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
- Where
- 55 sites in United States, Belgium and 6 more
- Volunteers
- 247 people
- Sponsor
- Aprea Therapeutics
Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
To assess the incidence of drug-related adverse events of Grade 3 or higher and the overall response associated with ipilimumab treatment
- Trial name
- NCT01611558
- Testing
- Ipilimumab
- Where
- 17 sites in United States
- Volunteers
- 40 people
- Sponsor
- Bristol-Myers Squibb
High Grade Serous Ovarian Cancer, Fallopian Tube Cancer
Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)
UP-NEXT is a double-blind, randomized, placebo-controlled study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks in patients with recurrent…
- Conditions
- High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- UP-NEXT (NCT05329545)
- Testing
- Upifitimab rilsodotin
- Where
- 30 sites in United States, Australia and 1 more
- Volunteers
- 20 people
- Sponsor
- Mersana Therapeutics
Fallopian Tube Cancer, Primary Peritoneal Cancer
A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
The primary purpose of the study is to evaluate the efficacy of R-DXd with or without bevacizumab as maintenance therapy compared with standard of care (SOC) in participants with platinum-sensitive ovarian cancer (PSOC) as…
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cancer, High-Grade Serous Ovarian Cancer, Endometrioid Epithelial Ovarian
- Trial name
- NCT07791732
- Testing
- R-DXd, Bevacizumab
- Volunteers
- 600 people
- Sponsor
- Daiichi Sankyo
Ovarian Cancer
Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer
The primary purpose of this study to determine if AZD2281 is effective and well tolerated in maintaining the improvement in your cancer after previous platinum-based chemotherapy
- Trial name
- NCT00753545
- Testing
- AZD2281
- Where
- 107 sites in United States, Australia and 15 more
- Volunteers
- 265 people
- Sponsor
- AstraZeneca
Fallopian Tube Cancer, Ovarian Cancer
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
To determine if AMG 386 plus pegylated liposomal doxorubicin (PLD) is superior to placebo plus PLD as measured by progression-free survival (PFS) The hypothesis for this study is that AMG 386 plus PLD will prolong PFS compared to…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01281254
- Testing
- AMG386 plus PLD
- Where
- 106 sites in United States, Australia and 16 more
- Volunteers
- 223 people
- Sponsor
- Amgen
Ovarian Cancer
Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
This is an open-label, single-arm, international, multicenter Multiple Patient Expanded Access Program (MPEAP). The program is designed to provide treatment access to olaparib tablets for patients with platinum-sensitive relapsed…
- Trial name
- NCT03079687
- Testing
- Olaparib tablets
- Where
- 13 sites in United States
- Sponsor
- AstraZeneca
Recurrent Platinum-sensitive Ovarian Cancer
Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Evaluation of the best therapeutic index for patients with platinum-sensitive ovarian cancer when treatment with bevacizumab and gemcitabine/carboplatin or with bevacizumab and PLD/carboplatin.
- Trial name
- NCT01837251
- Testing
- Carboplatin, PLD, Bevacizumab
- Where
- 193 sites in Australia, Austria and 4 more
- Volunteers
- 682 people
- Sponsor
- AGO Research GmbH
Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety and tolerability of IMGN151 when given as monotherapy and in combination with other…
- Conditions
- Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)
- Trial name
- NCT07024784
- Testing
- IMGN151, Carboplatin, Bevacizumab
- Where
- 21 sites in United States, Israel and 1 more
- Volunteers
- 377 people
- Sponsor
- AbbVie